language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
BLCOBLCO

$16.6

+0.17
arrow_drop_up1.03%
Current Market·update12 Nov 2025 21:00

$16.96

+0.37
arrow_drop_up2.23%
Pre-market·update13 Nov 2025 12:27
Day's Range
16.06-16.64
52-week Range
10.45-20.71

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2025-10-29
Next Earnings TimeBefore Market Open
Volume313.12K
Average Volume 30d517.78K

AI BLCO Summary

Powered by LiveAI
💰
-23.4
Valuation (P/E Ratio)
TTM P/E is negative, indicating losses. Further analysis needed.
📈
EPS Growth (YoY)
EPS has been negative in recent periods. Year-over-year growth cannot be determined with current data.
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Neutral
70

Bausch + Lomb demonstrates a solid position in the eye health sector with a diversified product range. However, recent financial performance shows profitability challenges, and technical indicators suggest a cautious outlook. A balanced approach considering its stable market presence and potential turnaround is recommended.

Moderate

Thematic

65

The aging global population and increasing awareness of eye care present long-term tailwinds for Bausch + Lomb. Emerging markets and advancements in ophthalmic technology offer growth avenues, though competition and regulatory hurdles are present.

Solid

Fundamental

75

Bausch + Lomb demonstrates robust revenue streams across its segments. However, recent net losses and negative free cash flow are concerning. The company holds significant assets, but debt levels have increased, impacting financial leverage.

Bearish

Technical

55

The stock price has experienced a significant decline over the past year and shows weakness across multiple timeframes. Key moving averages are signaling downward momentum, and most oscillators suggest a bearish trend.

FactorScore
Aging Population & Eye Health Awareness80
Technological Advancements in Vision Care75
Market Penetration in Emerging Markets60
Regulatory Landscape & Competition40
FactorScore
Valuation60
Profitability20
Growth70
Balance Sheet Health55
Cash Flow25
FactorScore
Trend Analysis30
Momentum40
Volume Confirmation45
Support & Resistance70

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (6)

Earnings Performance chevron_right

Earnings Surprise

Bausch + Lomb Corporation has exceeded earnings per share (EPS) estimates in 7 out of the last 10 quarters, with a notable average positive surprise of 21.8% in Q3 2023.

Valuation chevron_right

Attractive Price-to-Sales Ratio

The current Price-to-Sales (PS) ratio of 1.4 is below its trailing four-quarter average of 1.5 and competitive within the eye health industry.

Show More 🔒
thumb_down

Bearish Points (8)

Earnings Performance chevron_right

Negative Net Income

Bausch + Lomb Corporation has reported a net loss for the trailing twelve months (TTM) of -$211 million and for the fiscal year 2024 (-$317 million), indicating profitability challenges.

Valuation chevron_right

Negative P/E Ratio

The company has a negative Price-to-Earnings (P/E) ratio (TTM: -23.4, FY2024: -20.1), which is a strong indicator of current unprofitability and makes traditional P/E analysis unreliable.

Show More 🔒

Calendar

July 2025

30

Next Earnings Date

EPS Est.
Revenue Est.

H: $0.37

A: $0.09

L: $-0.01

H: 1.28B

A: 1.25B

L: 1.21B

Profile

Websitebausch.com
Employees (FY)13.5K
ISINCA0717051076
FIGI-

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Seasonals

2025
2024
2023
2022

Price Target

14.29 USD

The 39 analysts offering 1 year price forecasts for BLCO have a max estimate of 18.00 and a min estimate of 11.00.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
42M (11.88%)
Closely held shares
311M (88.12%)
353M
Free Float shares
42M (11.88%)
Closely held shares
311M (88.12%)

Capital Structure

Market cap
4.94B
Debt
4.78B
Minority interest
0.00
Cash & equivalents
305M
Enterprise value
9.42B

Valuation - Summary

Market Cap
4.95B
Net income
-211M(-4.27%)
Revenue
3.61B(73.05%)
4.95B
Market Cap
4.95B
Net income
-211M(-4.27%)
Revenue
3.61B(73.05%)
Price to earning ratio (P/E)-23.40x
Price to sales ratio (P/S)1.40x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
4.79B
COGS
1.87B
Gross Profit
2.92B
OpEx
2.73B
Operating Income
188M
Other & Taxes
505M
Net Income
-317M

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒